B+
Bull case
25%
Probability
Target price
$2.20
+58.3% vs current
CBUS
CibusBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.30
-6.5% vs current
B-
Bear case
30%
Probability
Target price
$0.60
-56.8% vs current
AI sentiment snapshot
Latest data as of 2026-04-30
Recent news sentiment (30D)
+52.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+43.3
Score
AI commentary
Primary evidence supports a cautious monitoring stance rather than a strong directional call. Recent news and filing evidence point to real rice-program milestones, but the evidence base remains thin, direct peers are weak, and social-context data was not provided. The deterministic prior is mildly positive, but uncertainty and financing risk keep conviction capped.
RankAlpha Sentiment Codex - 2026-04-30
Open full AI memoEvidence flagged
Coverage is limited for this name, so the memo relies on a thinner evidence base.; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-09-30catalystRunway and financing overhang remains the nearest-term issueHigh impact
Cibus said cash was $9.9 million at December 31, 2025 and that, including $19.8 million of January 2026 net offering proceeds plus cost-saving actions, existing cash should fund operations only into late Q3 2026. Management also said the board continues to evaluate a full range of strategic alternatives, so financing, dilution, or transaction-structure risk remains central to the thesis [#10-K-2026-03-17][#PR-2026-03-17][#PR-2026-01-29].
2026-12-31event2026 conversion of rice partner activity into commercial agreementsHigh impact
Management's 2026 milestone list includes expanding rice seed relationships across the U.S., Latin America, and India and developing full commercial agreements for two existing Latin American rice seed partners. Actual agreement conversion would be the clearest operating proof point that the royalty model is moving beyond development-stage collaboration [#PR-2026-03-17].
2027-12-31catalystRice launch path remains the main upside anchor but is still execution dependentHigh impact
Cibus reiterated that its HT1 and HT3 rice program is on track for targeted launches in Latin America in 2027 and the U.S. in 2028, with management framing the opportunity as 5-7 million peak addressable acres and more than $200 million in annual addressable royalties at peak. That is the core long-duration upside, but it still depends on partner execution, field progress, regulatory progress, and commercialization follow-through [#PR-2026-03-17].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-30 • Updated nightlySource: Internal modelMethodology